Royalty Pharma plc | Business Operations | Business Contracts

Second Amended and Restated Management and Services Agreement dated October 3, 2022, among Royalty Pharma Investments 2019 ICAV and RP Management, LLC (Filed With SEC on November 8, 2022)

Research, Development and Commercialization Agreement, dated May 24, 2004, between the Cystic Fibrosis Foundation Therapeutics Incorporated and Vertex Pharmaceuticals Inc., as... (Filed With SEC on October 13, 2020)

Amended and Restated Management and Services Agreement dated October 3, 2022, among Royalty Pharma Holdings Limited and RP Management, LLC (Filed With SEC on November 8, 2022)

Amended and Restated Management and Services Agreement dated October 3, 2022, among the Company and RP Management, LLC (Filed With SEC on November 8, 2022)

Amended and Restated Management and Services Agreement dated June 11, 2020, among Royalty Pharma Investments 2019 ICAV and RP Management, LLC (Filed With SEC on October 13, 2020)

Amendment No. 7 to Research, Development and Commercialization Agreement, dated September 1, 2016, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis... (Filed With SEC on October 13, 2020)

Amendment No. 5 to Research, Development and Commercialization Agreement, dated April 1, 2011, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Filed With SEC on October 13, 2020)

Amendment No. 2 to Research, Development and Commercialization Agreement, dated January 1, 2006, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Filed With SEC on October 13, 2020)

Amendment No. 1 to Research, Development and Commercialization Agreement, dated January 6, 2006 by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Filed With SEC on October 13, 2020)

Management and Services Agreement dated June 15, 2020, among the Company and RP Management, LLC (Filed With SEC on October 13, 2020)

Amended and Restated Management and Services Agreement dated June 11, 2020, among Royalty Pharma Investments 2019 ICAV and RP Management, LLC (Filed With SEC on June 19, 2020)

Management and Services Agreement dated June 15, 2020, among the Company and RP Management, LLC (Filed With SEC on June 19, 2020)

Research, Development and Commercialization Agreement, dated May 24, 2004, between the Cystic Fibrosis Foundation Therapeutics Incorporated and Vertex Pharmaceuticals Inc., as... (Filed With SEC on May 22, 2020)

Form of Amended and Restated Management and Services Agreement, dated, 2020, among Royalty Pharma Investments 2019 ICAV and RP Management, LLC (Filed With SEC on May 22, 2020)

Amendment No. 7 to Research, Development and Commercialization Agreement, dated September 1, 2016, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis... (Filed With SEC on May 22, 2020)

Amendment No. 5 to Research, Development and Commercialization Agreement, dated April 1, 2011, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Filed With SEC on May 22, 2020)

Amendment No. 2 to Research, Development and Commercialization Agreement, dated January 1, 2006, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Filed With SEC on May 22, 2020)

Amendment No. 1 to Research, Development and Commercialization Agreement, dated January 6, 2006 by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation... (Filed With SEC on May 22, 2020)

Form of Management and Services Agreement, dated , 2020, among Royalty Pharma plc and RP Management, LLC (Filed With SEC on May 22, 2020)

Royalty Pharma plc (52) | Business Operations (19)